Home  >  Research  >  Labs  >  Cancer Program  >  LIVER DISEASE AND CARCINOGENESIS

RESEARCH OVERVIEW

Our research group focuses on the liver progenitor/stem cell (LPSC) which we identify in patients with alcoholic liver disease (ALD), hepatitis C (HCV), genetic hemochromatosis (GH) and non-alcoholic fatty liver disease (NAFLD). An objective of our research is to utilise their presence as a diagnostic to detect early stages of pathology and their abundance as an indicator of disease severity. Since ALD, GH, HCV and NAFLD increase the likelihood of developing hepatocellular carcinoma (HCC), the LPSCs may also be useful as a prognostic for patients who will develop liver cancer.

We are well-placed to undertake these studies as we have a monoclonal antibody that detects the LPSCs in liver biopsies. Our recent studies suggest that the protein this antibody binds to is present in the blood of patients who harbour LPSCs in their liver. This raises the possibility of developing a blood test that informs clinicians of the state of the patient’s liver.

The LPSC is present in diseased liver because it has an important role in repairing the damaged organ. It is a functional stem cell that can produce cholangiocytes that make up the bile ducts; or it can produce hepatocytes that are responsible for the major functions of the liver. To better study this important liver cell, we have established LPSC lines from both the mouse and human to understand what makes them grow and how they decide between generating cholangiocytes and hepatocytes.

This work has produced a valuable resource in the form of LPSC lines that are non-cancerous and others that are tumorigenic. This provides a platform for screening and testing for anti-liver cancer drugs that are selectively effective against liver cancer cells.

 

Emeritus Professor George Yeoh

Emeritus Professor George Yeoh

Liver Disease and Carcinogenesis

Read more

LATEST NEWS

Dr Moira Clay takes up new Deputy Director role at the Perkins

The Harry Perkins Institute of Medical Research is delighted to welcome Dr Moira Clay as Deputy Director. Moira will commence in this new role on 4 February 2025. Moira will support Perkins Chief Executive Officer, Professor Peter Leedman AO in operational research matters, and steward the research strategy of the…

Read More

Researchers discover blood markers that could predict mesothelioma treatment success

A groundbreaking study by researchers at the National Centre for Asbestos Related Diseases (NCARD), The Kids Research Institute and the Harry Perkins Institute of Medical Research (the Perkins) has identified blood markers that could help predict how well mesothelioma patients respond to treatment. This discovery could transform how treatment decisions…

Read More

Perkins researcher awarded Raine Priming Grant

Dr Mridul Johari from the Perkins Rare Disease Genetics and Functional Genomics Group has been awarded a prestigious Raine Priming Grant from the Raine Medical Research Foundation. Dr Johari’s project, From Coding to Cryptic – Exploring the RNA World of Inclusion Body Myositis (IBM), has secured $247,815.63 in funding to…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS